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Abstract  22 
 23 
Maternal obesity is growing in prevalence and associated with increased morbidity and 24 
mortality for both mother and child. Women who are obese during pregnancy have a 25 
greater risk of metabolic complications such as gestational diabetes mellitus (GDM) as well 26 
as type 2 diabetes after pregnancy. Children of obese and/or GDM mothers have an 27 
increased susceptibility to congenital abnormalities and a range of cardio-metabolic 28 
disorders. The placenta is at the interface of the maternal and fetal environments and, its 29 
function per se, plays a major role in dictating the impact of maternal health on fetal 30 
development. Here, we review the literature on how placental function is affected in 31 
pregnancies complicated by obesity, pre-gestational and gestational diabetes. The focus is 32 
on the availability of three key substrates in these conditions: glucose, lipids, and amino 33 
acids, and their impact on placental metabolic activity. Maternal obesity and diabetes are 34 
not always associated with fetal compromise and the adaptation of the placenta may 35 
partially determine the outcome. Understanding the differences in metabolic adaptation 36 
may open avenues for therapeutic development.  37 
 38 
 39 
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1. Introduction 41 
 42 
The global prevalence of overweight, obesity, and diabetes mellitus is increasing [1]. 43 
In developed nations, one third of pregnant women are overweight or obese [2] and 5-10% 44 
have diabetes in pregnancy [3]. In these complicated pregnancies, physiological changes are 45 
exaggerated, including alterations to lipoprotein levels and enhanced gluconeogenesis [4]. 46 
High maternal weight, dyslipidemia, and/or hyperglycemia place mother and child at risk, 47 
with the most common adverse outcome being high birth weight (macrosomia) [5-12]. 48 
Large for gestational age infants born to women with GDM have a higher percent body fat 49 
when compared to infants from uncomplicated pregnancies [13] and ~70% of mothers [14] 50 
and offspring [15] will develop type 2 diabetes in later life.  51 
The influence of maternal disease on fetal outcomes is governed, to a large extent, 52 
by the placenta. In maternal obesity and hyperglycemia, placental size is greater and 53 
structural changes including thrombosis may be evident [16-19]. There are three main 54 
mechanisms that regulate fetal exposure to maternal nutrients: direct placental transfer, 55 
placental consumption, and placental conversion into alternative sources of fuel [20, 21]. 56 
While direct transfer is often regarded as the predominant pathway in regulating maternal-57 
fetal exchange, the placenta has a high metabolic activity, which is affected by an 58 
obesogenic and/or diabetogenic environment. Alterations in placental metabolism may 59 
serve as a checkpoint to regulate fetal exposure and, ultimately, determine the degree of 60 
influence that abnormal maternal metabolism has on fetal growth and development (Figure 61 
1) [22].  62 
 63 
2. Glucose transport and metabolism 64 
 65 
Glucose is the predominant source of energy for the fetus and placenta [23]. There is 66 
limited capacity for the fetus to generate its own glucose and almost all of fetal glucose is 67 
derived from the mother [24, 25]. Net glucose transfer is determined by placental 68 
transporter density, the maternal-fetal concentration gradient, and placental glucose 69 
metabolism [26].  70 
Glucose transfer across the placenta occurs via the family of facilitated glucose 71 
transporters (GLUTs). In the human syncytiotrophoblast, GLUT1 is expressed in both 72 
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membrane fractions but there is a three- to four-fold greater expression in the microvillous 73 
versus basal membranes [27]. This ensures greater transport capacity from the maternal 74 
side and glucose transfer across the fetal side is considered a rate-limiting step. The density 75 
of GLUT1 in the basal membrane increases in the first half of pregnancy and subsequently 76 
plateaus suggesting that early pregnancy determines fetal demands for glucose transfer. 77 
GLUT1 is primarily localized to the syncytiotrophoblast but also expressed in 78 
cytotrophoblasts and fetal endothelial cells. GLUT3 is expressed in fetal arterial endothelial 79 
cells but its microvillous expression remains controversial; there are reports for its absence 80 
[28] and presence [29] at this site. The two known splice variants of GLUT9 are also 81 
expressed in placentae, with GLUT9a localized to the basal membrane and GLUT9b to the 82 
microvillous [30, 31]. GLUT4 is localized to stromal cells and not considered to contribute 83 
significantly to transplacental glucose transfer [32]. Other GLUT isoforms are either absent 84 
or expressed at very low levels in the human placenta [26]. Insulin is not considered to 85 
affect placental glucose transfer or metabolism, at least directly.  86 
In a recent study consisting of 40 women with uncomplicated pregnancies, placental 87 
glucose transfer was quantified in vivo during a planned caesarean section [33]. The 88 
concentration of glucose was higher on the maternal (4.71 mmol/L) versus the fetal (3.48 89 
mmol/L) sides, and this gradient was strongly and positively correlated with fetal glucose 90 
consumption. Maternal plasma glucose levels alone and uteroplacental glucose extraction 91 
did not correlate with fetal glucose consumption. These findings indicate that, in normal 92 
pregnancy, fetal glucose demands dictate transplacental glucose transport, rather than 93 
maternal blood glucose levels or uteroplacental glucose requirements.  94 
In vitro experiments demonstrate that 25% of glucose that enters the placenta is 95 
metabolized, predominately into lactate via glycolysis, and the remaining 75% is delivered 96 
unchanged to the fetus [34]. However, the low metabolic rate in these experiments is 97 
explained by a low oxygen supply, which underestimates the magnitude of glucose 98 
oxidation [35]. The placenta has also been shown to synthesize glycogen [36] and, in healthy 99 
placentae explants, glucose can be incorporated into lipids [37]. Furthermore, the placenta 100 
expresses glucose-6-phosphatase suggesting capacity for gluconeogenesis [38]. The 101 
feasibility of carrying out advanced carbon tracer and imaging studies in humans is limited; 102 
however, future in vivo studies in other mammalian species may help to ascertain the fate 103 
of glucose once delivered to the uteroplacental unit. 104 
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 105 
2.1 Maternal overweight and obesity 106 
 107 
The association between excessive maternal weight and adverse fetal outcomes, 108 
including macrosomia, is well established [5] but the mechanisms describing this link have 109 
not been elucidated. Birth weight, which positively correlates with maternal BMI, also 110 
correlated with GLUT1 expression in isolated basal membranes [39]. However, basal 111 
membrane GLUT9, and microvillous GLUT1 and GLUT9 were not increased in overweight or 112 
obese women, nor was glucose transfer across either membrane. 113 
Pregnancies complicated by maternal overweight or obesity are associated with a 114 
proinflammatory state [40] and this has been proposed to underlie fetal macrosomia [22]. A 115 
limitation of placental explant experiments is that modulatory effects of other factors, such 116 
as inflammatory cytokines, growth factors, hormones, and other substrates, are often 117 
ignored [39]. Visiedo et al. focused on the role of placental-derived hepatocyte growth 118 
factor (HGF) in modulating placental metabolism in maternal obesity [19]. HGF was 119 
increased in amniotic fluid and placental tissue of obese women, which increased 120 
esterification, de novo fatty acid synthesis, and accumulation of placental triglycerides. HGF 121 
also stimulated placental glucose uptake and utilization, which was facilitated by 122 
augmented GLUT1 expression. Another cytokine, resistin, stimulated glucose uptake and 123 
GLUT1 expression in trophoblast cells [41]. TNFα applied to syncytiotrophoblasts from lean 124 
women showed reduced oxygen consumption rates in female, but not male, placentae [42]. 125 
However, this cannot be attributed solely to reduced glucose oxidation as the assay medium 126 
contained glucose, pyruvate, and glutamine substrates. These data indicate that the 127 
inflammatory profile associated with maternal overweight and obesity stimulates placental 128 
glucose uptake, yet further research is necessary to describe the changes that occur to 129 
placental glucose metabolism in vivo.  130 
 131 
2.2 Pre-existing diabetes and GDM 132 
 133 
Even in pregnancies of women with well-controlled diabetes, macrosomia remains 134 
common [18, 43, 44]. In long-standing insulin-dependent diabetes, increasing birth weight 135 
correlated with increasing glucose uptake and GLUT1 protein expression in basal, but not 136 
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microvillous, syncytiotrophoblast membrane vesicles [18]. Similarly, in pregnancies of pre-137 
existing diabetes and GDM, albeit well-controlled at term, others reported upregulated 138 
GLUT1 expression (two-fold) and glucose transport (40%) in isolated syncytiotrophoblast 139 
basal membranes [45]. Once again, GLUT1 expression and glucose uptake were unaffected 140 
in microvillous membranes, which is consistent with studies in high maternal BMI [39]. Basal 141 
membrane GLUT9a is also increased in placentae from pre-existing and gestational diabetes, 142 
while microvillous membrane GLUT9b is increased only in response to exogenous insulin 143 
[31]. These data suggest that, in diabetes, the capacity for transplacental glucose transfer 144 
across the basal membrane is increased and fetal macrosomia is not merely due to 145 
increased maternal glucose. Given that basal membrane GLUT1 expression increases in 146 
early pregnancy (and plateaus thereafter), this may represent a critical period whereby 147 
transient metabolic abnormalities stimulate further increases in GLUT1 expression [18]. The 148 
expression of basal membrane GLUT1 is insensitive to glucose concentrations in the 149 
physiological range [46]. Thus, the regulation of placental glucose transporters may be 150 
multifactorial. Hyperglycemia-induced increases in fetal growth hormones, i.e. insulin and 151 
insulin-like growth factor-1 (IGF-1), have been regarded as potential factors as have other 152 
glycolytic intermediates and uteroplacental hypoxia. Of note, placental expression levels of 153 
GLUT3 and GLUT4 are unaltered by insulin-dependent or -independent diabetes [26].  154 
A recent study reported that placental explants from GDM pregnancies had a two- to 155 
three-fold higher glucose uptake and a 50% reduction in fatty acid oxidation [47]. Placentae 156 
from normoglycemic pregnancies cultured in high glucose had reduced fatty acid oxidation, 157 
along with increased esterification and accumulation of triglycerides [37]. The mechanism 158 
proposed was inhibition of carnitine palmitoyltransferase (CPT1) activity by a glucose-159 
derived by-product, malonyl-CoA. These findings were in agreement with a later study in 160 
maternal obesity, showing that heightened glucose metabolism in placental explants 161 
reduced fatty acid oxidation [19]. In women with pre-existing diabetes [48] or GDM [49], 162 
placental activity of mitochondrial electron transport chain complexes was reduced. In 163 
GDM, mitochondrial oxygen consumption was reduced, along with increased placental 164 
expression of glycolytic enzymes and LDH (marker of aerobic glycolysis) [49]. However, 165 
these women had been treated with either insulin or glyburide so effects on placental 166 
glucose metabolism cannot be definitively attributed to GDM. Collectively, these data 167 
suggest that placental glucose uptake is augmented and shunted into glycolytic pathways in 168 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
maternal hyperglycemia, and that downstream changes to fatty acid metabolism may 169 
provide a mechanistic link between maternal metabolic abnormalities and fetal fat 170 
accretion.  171 
 172 
3. Lipid transport and metabolism 173 
 174 
Fetal growth and development is also supported by free fatty acids and the 175 
constituent fatty acids and cholesterol that are transported in maternal lipoproteins. 176 
Markers of fetal cholesterol synthesis are very low in early pregnancy and increase only 177 
after 19 weeks gestation [50]. Placental transfer of lipoproteins is facilitated by lipoprotein 178 
receptors, lipases (lipoprotein lipase (LPL), endothelial lipase (EL), hormone sensitive lipase 179 
(HSL) and adipose triglyceride lipase (ATGL)), and fatty acid binding proteins (FABPs) (Figure 180 
2) [51-59]. Free fatty acids and lipoprotein/triglyceride fatty acids are transported into the 181 
placenta by plasma membrane FABP (FABPpm), FABP1-5, fatty acid translocase (FAT/CD36), 182 
and fatty acid transport proteins (FATP)1-4 and 6. Placental cholesterol uptake from 183 
lipoproteins occurs through scavenger receptor class B type I receptor (SRBI), low-density 184 
lipoprotein receptor (LDLR), and very low density lipoprotein receptor (VLDLR), and its efflux 185 
is mediated by ATP binding cassette transporter A1 and G1 (ABCA1 and ABCG1) [60]. Uptake 186 
of chylomicron remnant particles has also been demonstrated in the rodent placenta [61]. 187 
Maternal obesity and maternal hyperglycemia, in the setting of pre-existing diabetes 188 
and GDM, influence placental lipid transport and their frequent co-existence makes 189 
assessing the influence of each condition challenging. 190 
 191 
3.1 Maternal overweight and obesity 192 
 193 
Maternal obesity alters aspects of the hormonal and inflammatory milieu to which 194 
the placenta is exposed. These aspects include insulin and adipokines, such as leptin and 195 
adiponectin as well as cytokines [62, 63], and have been hypothesized to alter placental 196 
function by influencing nutrient sensing pathways including the insulin/IGF-1, mechanistic 197 
target of rapamycin (mTOR), and peroxisome proliferator-activated receptor (PPAR)-α 198 
pathways. In a mouse model of maternal obesity, activation of these pathways was 199 
observed in placental tissue [64]. Another mouse study showed that supplementation with 200 
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adiponectin (usually lower in obese women) normalized overall insulin sensitivity in the dam 201 
and placental nutrient sensing pathways [65].  202 
Maternal high cholesterol, diabetes, and obesity influence placental expression of 203 
receptors and regulators of fatty acid and cholesterol transport. In ewes, maternal obesity 204 
was associated with increased cholesterol and triglyceride concentrations in fetal and 205 
maternal blood [66]. This was associated with elevated FATP4 protein expression as well as 206 
increased mRNA and protein expression of PPAR-γ. In a mouse model of maternal obesity, 207 
fetal liver contained 10-fold increased lipid droplets along with increased FATP6 and FABP3 208 
protein expression in trophoblast plasma membranes [67].  209 
In humans, maternal obesity, in concert with insulin resistance, was associated with 210 
altered placental expression of genes related to cholesterol uptake and metabolism [68]. In 211 
women with high cholesterol, placental fatty acid synthase (FAS) and sterol regulatory 212 
element-binding protein (SREBP)-2 expression were increased, with no alteration to SREBP-213 
1 or HMG-CoA reductase (HMGR) [69]. One of the functions of cholesterol in the placenta is 214 
steroid synthesis, thus the production of placental hormones may be affected by maternal 215 
obesity. Lassance et al. reported obesity was associated with lower maternal plasma 216 
estradiol and progesterone levels, with reduced placental mitochondrial cholesterol and 217 
translocator protein (TSPO) expression [70].  218 
Obesity, and the degree of maternal weight gain during pregnancy, also influences 219 
fatty acid uptake in human placenta. In women who gained weight in excess of BMI-specific 220 
guidelines, increased placental expression of system A amino acid transporter (SNAT)-1 and 221 
decreased expression of FABP3 and other genes involved in nutrient transport were evident 222 
[71]. At term, an examination of placentae from six obese women revealed increased CD36 223 
mRNA and protein expression, decreased FATP4 and FABP1 mRNA and protein expression 224 
and FABP3 protein expression, and increased LPL activity, with no change in PPAR-α, PPAR-225 
δ, or PPAR-γ mRNA or protein expression [56]. The authors also described decreased 226 
microvillous cytotrophoblast transport of radiolabeled linoleic acid in cells isolated from 227 
placentae of the obese women. The effect of maternal obesity on placental transfer of fatty 228 
acids may be dependent on infant gender, with oleic acid uptake in term placentae reduced 229 
in males and increased in females, and a similar trend was evident for arachidonic and 230 
docosahexanoic acid [72]. The same study also described a gender-dependent, but not BMI-231 
dependent, effect on CD36 and FABP5 gene expression. 232 
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 233 
3.2 Pre-existing diabetes and GDM 234 
 235 
Similar to obesity, pre-existing diabetes and GDM are associated with an altered 236 
maternal environment, including changes in circulating adipokines, growth hormones, and 237 
insulin, which can influence placental development and function. A study of 40 women 238 
showed that the insulin secretory response to an IV glucose tolerance test was positively 239 
associated with placental volume in early pregnancy [73]. In women with GDM, insulin and 240 
leptin levels are elevated, and there is activation of their receptors in the placenta [74]. 241 
Treatment with insulin in women with pre-existing diabetes and GDM positively correlates 242 
with placental expression of vascular endothelial (VE)-cadherin and β-catenin in 243 
fetoplacental vessels [75], supporting the notion that maternal insulin affects placental 244 
function directly. 245 
Both pre-existing diabetes and GDM affect placental lipid processing but studies 246 
have primarily examined maternal type 1, rather than type 2, diabetes mellitus. To the best 247 
of our knowledge, only one study has assessed lipid processing in placentae of women with 248 
type 2 diabetes and reported decreased protein expression of PPAR-α and PPAR-γ, 249 
unchanged PPAR-δ, with increased placental lipids, nitric oxide, and peroxide content [76]. 250 
Using primary placental cell cultures, a characterization of genes involved in metabolism 251 
showed that lipid, rather than glucose, pathways were commonly activated in women with 252 
GDM [55]. Lipid modifications were not as common in placentae from women with type 1 253 
diabetes and there was preferential activation of glycosylation and acylation pathways. In 254 
term placentae from normal weight or overweight/obese women with GDM, there were 255 
variable effects on lipid pathways depending on BMI category, including alterations in the 256 
expression of SRBI, LDLR, VLDLR, ABCA1, ABCG1, and proprotein convertase subtilisin/kexin 257 
type 9 [77].  258 
Placental lipase expression in women with pre-existing diabetes, GDM, and obesity 259 
also show variable results, possibly due to differences in metabolic control [53], or the 260 
degree of maternal adiposity [57], triglycerides, or free fatty acids [78, 79]. Placental LPL 261 
DNA methylation is lower in GDM and negatively correlated with glucose and HDL 262 
cholesterol levels [80]. Phospholipid transfer protein (PLTP) mRNA expression is increased 263 
and not influenced by BMI in women with GDM [81]. Insulin treatment of endothelial cells 264 
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isolated from placental vessels increased PLTP levels and activity [81]. Several of the FABPs, 265 
specifically -1, -4, and -5, were reported to be increased in placentae from women with pre-266 
existing type 1 diabetes or GDM [54, 55]. In pregnancies complicated by diabetes, raised 267 
NEFA levels may contribute to fetal macrosomia [82]. It is thought that placental transfer of 268 
maternal NEFA is increased, transported into fetal adipocytes, and esterified into 269 
triglycerides. Trophoblasts isolated from the placentae of women with GDM show reduced 270 
uptake of long chain polyunsaturated fatty acids [83] and two-fold greater triglyceride 271 
esterification in placental explants [47]. Placentae from women with type 1 diabetes 272 
showed increased placental triglyceride content [53], and increased LPL activity where 273 
infants were macrosomic [54] and decreased LPL expression where infants were of healthy 274 
weight [55]. In maternal type 1 diabetes, endothelial lipase expression in placenta was 275 
increased [53].  276 
Placental NEFA esterification into triglycerides is thought to be increased in 277 
pregnancies complicated by hyperglycemia and/or obesity as a regulatory step to limit fatty 278 
acid transfer to the fetus [37]. However, there is no direct evidence to support this notion 279 
and earlier studies indicate that de novo fatty acid synthesis is not a significant contributor 280 
to triglyceride accumulation in diabetic placentae [84]. In fact, the accumulation of placental 281 
triglycerides may contribute to the proinflammatory state of complicated pregnancies. GDM 282 
has been associated with increased levels of inflammatory cytokines (IL-1β and TNFα) 283 
correlating with the induction of FAS expression [69]. 284 
 285 
4. Amino acid transport and metabolism  286 
 287 
Amino acids are important substrates for the formation of proteins and nucleic acids 288 
in the fetus and placental transport is a tightly regulated process. Maternal amino acids are 289 
transported against the concentration gradient with placental intervillous concentrations 290 
generally exceeding maternal concentrations by two-fold [85, 86]. The concentrations in the 291 
umbilical vein mirror those of the placental intervillous space for most amino acids [85]. The 292 
high amino acid concentrations in the placental intervillous blood likely reflect active 293 
transport of amino acids from the maternal circulation to the intervillous space by 294 
syncytiotrophoblasts [85]. 295 
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Amino acid transport in the placenta is facilitated by carrier proteins that are 296 
expressed on the syncytiotrophoblast microvillous and basement membranes [87]. There 297 
are 15 amino acid transport systems expressed in the placenta, seven of which are 298 
dedicated to transport of neutral amino acids (Table 1) [88]. The seven different systems for 299 
neutral amino acid transport vary in their substrate specificity and sodium dependency. 300 
Some amino acids are selectively transported by a single system whereas others can be 301 
transported by multiple transport systems.  302 
Most amino acids are transported between the maternal and fetal circulation in both 303 
directions. Some amino acids (aspartate and glutamate) have no net transport in either 304 
direction [86], with the placenta accumulating these acidic amino acids. Glutamate is 305 
transported from fetal liver to the placenta where it is converted to glutamine, released 306 
back to the fetus, and serves as a source of energy and substrate for protein and nucleic 307 
acid synthesis [89]. The majority of studies into placental amino acid transport have clearly 308 
defined the relationship to fetal growth restriction. In obesity and diabetes, studies have 309 
primarily focused on neutral amino acid transport through systems A and L.  310 
 311 
4.1 Maternal overweight and obesity 312 
 313 
In obesity, altered placental neutral amino acid transport via system A contributes to 314 
macrosomia and large for gestational age infants [90, 91]. Placental gene and protein 315 
expression of SNAT1, and protein expression and activity of SNAT2 are increased [90, 92] 316 
but SNAT4 activity is decreased [91]. Increased SNAT2 activity is associated with higher 317 
circulating levels of the inflammatory cytokines, IL-6 and TNFα. These isoform-specific 318 
changes indicate that it is difficult to determine the overall effects of obesity on amino acid 319 
transport. Furthermore, relatively small sample sizes and varying degrees of obesity may 320 
contribute to the divergent results. Gender may further contribute to the disparity, with 321 
male, but not female, offspring showing positive correlations between placental SNAT1 322 
gene expression and excess gestational weight gain [93]. Dietary fat intake alters placental 323 
system A amino acid transport in mice, which may also occur in human placenta [94]. 324 
However, the protein expression and activity of the system L amino acid transporter (LAT) is 325 
not different in obese women, not affected by gestational weight gain, nor correlated to 326 
infant birth weight [95]. Maternal plasma taurine levels are higher in obese women than in 327 
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normal-weight women with similar concentrations in the fetal circulation [96]. This is likely 328 
due to significantly decreased activity, but not amount, of the placental microvillous B 329 
transporter system in obesity and is independent of leptin and IL-6 [97].  330 
The results indicate that obesity alters placental amino acid transport and may 331 
contribute to the fetal overgrowth commonly associated with high maternal BMI. This could 332 
be mediated by increased cytokine levels or altered levels of metabolic hormones including 333 
leptin, adiponectin, insulin, and IGF-1 and may involve signalling through insulin, mTOR, and 334 
STAT3 pathways to increase the expression of placental amino acid transporters (Figure 3) 335 
[90, 98, 99]. The effects of other hormones that are altered by maternal obesity such as 336 
fibroblast growth factor 21 (FGF21), adipocyte fatty acid-binding protein (AFABP), resistin, 337 
progranulin, and apelin on placental amino acid transport have not yet been investigated. 338 
 339 
4.2 Pre-existing diabetes and GDM 340 
 341 
In type 1 diabetes, amino acid concentrations in maternal plasma have been 342 
compared to weight-matched, normoglycemic plasma, with differences becoming more 343 
pronounced as pregnancy progresses [100]. In early pregnancy, only valine, lysine, and 344 
citrulline were increased and in mid-gestation, serine, lysine, proline, and arginine levels 345 
were higher but taurine levels were lower. In late gestation, amino acid plasma 346 
concentrations are higher overall with significantly higher serine, threonine, lysine, histidine, 347 
proline, and arginine concentrations in type 1 diabetes. These differences disappear post-348 
partum and represent specific pregnancy-induced changes to amino acid metabolism. Since 349 
these women with type 1 diabetes were lean, increased birth weight may be partially 350 
explained by the increased circulating amino acids. Indeed, serine in particular, but not 351 
glucose, significantly correlated with birth weight in type 1 diabetes.  352 
In women with type 1 diabetes, placental expression of system A neutral amino acid 353 
transporters has been reported as both increased [87] and reduced [101]. These differences 354 
may be due to small sample sizes and between-study differences in the demographic and 355 
clinical characteristics of the participants. However, since the supply of amino acids from 356 
the maternal circulation is increased in type 1 diabetes, changes to the expression and/or 357 
activity of amino acid transporters in placentae of women with type 1 diabetes may exist.  358 
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There are no reports on placental amino acid transport in the setting of type 2 359 
diabetes. The clinical characteristics of women with type 2 diabetes resemble those of 360 
maternal obesity and/or GDM and it can be surmised that changes in placental amino acid 361 
transport are also present in women with type 2 diabetes.  362 
In women with well-controlled GDM, the maternal concentration of ornithine only 363 
was increased [102]. However, in umbilical venous blood, methionine, isoleucine, isoleucine, 364 
phenylalanine, ornithine, glutamate, proline, and alanine were increased and glutamine was 365 
decreased. In large for gestational age infants from mothers with type 1 diabetes or GDM, 366 
placental leucine transport was increased [103]. These disparities between maternal and 367 
fetal concentrations indicate that placental amino acid transport is altered in GDM. High 368 
glucose and leptin concentrations, as commonly observed in GDM, but not insulin or TNFα, 369 
inhibited placental uptake of methionine via LAT in vitro [104]. In GDM, placental gene 370 
expression of IL-1β and TNFα were increased [105], which could result in higher expression 371 
of SNAT2, similar to what is observed in obesity. Since obesity is a risk factor for the 372 
development of GDM, the effects of pro-inflammatory cytokines and hormones including 373 
insulin, adiponectin, and leptin on amino acid transport in the placenta could be further 374 
compounded.   375 
 376 
5. Conclusions  377 
 378 
In pregnancies complicated by obesity and/or diabetes, glucose appears to be the 379 
preferred energy substrate for placental metabolism, its uptake increasing in both states. 380 
Glucose transport and metabolism, however, are not merely modulated by maternal 381 
glucose per se, but likely to involve a complex and dynamic interplay with fetal growth 382 
factors and other energy substrates. Lipid processing and transfer by the placenta is 383 
influenced in complex ways by maternal BMI, glucose status, and inflammation. Amino acid 384 
transport is also affected by inflammation and increased in obesity and/or diabetes in 385 
pregnancy. Whilst an increase in maternal lipids appears to be the predominant substrate in 386 
driving fetal macrosomia in maternal overweight, obesity, and/or diabetes, the combined 387 
increase in all fuels likely contributes to the increased risk of adverse fetal outcomes.  388 
 389 
 390 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
Conflict of interest 391 
None.  392 
 393 
Acknowledgments 394 
LAG was supported by a fellowship from the National Health and Medical Research Council 395 
(NHMRC) and Heart Foundation (Australia). HLB is supported by an Australian Diabetes 396 
Society – Skip Martin Early Career Research Fellowship. This review was generated as part of 397 
the Queensland Perinatal Consortium Inaugural Conference held on July 15th 2016 in 398 
Brisbane, Queensland Australia. The conference was supported by an Intra-Faculty 399 
Collaborative Workshop grant from the Faculty of Medicine, The University of Queensland. 400 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
15 
 
References 
[1] N.C.D.R.F. Collaboration, Worldwide trends in diabetes since 1980: a pooled analysis of 
751 population-based studies with 4.4 million participants, Lancet 387(10027) (2016) 1513-
30. 
[2] H.D. McIntyre, K.S. Gibbons, V.J. Flenady, L.K. Callaway, Overweight and obesity in 
Australian mothers: epidemic or endemic?, Med J Aust 196(3) (2012) 184-8. 
[3] L. Guariguata, U. Linnenkamp, J. Beagley, D.R. Whiting, N.H. Cho, Global estimates of the 
prevalence of hyperglycaemia in pregnancy, Diabetes Res Clin Pract 103(2) (2014) 176-85. 
[4] E. Herrera, Lipid metabolism in pregnancy and its consequences in the fetus and 
newborn, Endocrine 19(1) (2002) 43-55. 
[5] F. Galtier-Dereure, C. Boegner, J. Bringer, Obesity and pregnancy: complications and 
cost, Am J Clin Nutr 71(5 Suppl) (2000) 1242S-8S. 
[6] H.S.C.R. Group, B.E. Metzger, L.P. Lowe, A.R. Dyer, E.R. Trimble, U. Chaovarindr, D.R. 
Coustan, D.R. Hadden, D.R. McCance, M. Hod, H.D. McIntyre, J.J. Oats, B. Persson, M.S. 
Rogers, D.A. Sacks, Hyperglycemia and adverse pregnancy outcomes, N Engl J Med 358(19) 
(2008) 1991-2002. 
[7] A. Yessoufou, K. Moutairou, Maternal diabetes in pregnancy: early and long-term 
outcomes on the offspring and the concept of "metabolic memory", Exp Diabetes Res 2011 
(2011) 218598. 
[8] G. Di Cianni, R. Miccoli, L. Volpe, C. Lencioni, A. Ghio, M.G. Giovannitti, I. Cuccuru, G. 
Pellegrini, K. Chatzianagnostou, A. Boldrini, S. Del Prato, Maternal triglyceride levels and 
newborn weight in pregnant women with normal glucose tolerance, Diabet Med 22(1) 
(2005) 21-5. 
[9] D.A. Lawlor, A. Fraser, R.S. Lindsay, A. Ness, D. Dabelea, P. Catalano, G. Davey Smith, N. 
Sattar, S.M. Nelson, Association of existing diabetes, gestational diabetes and glycosuria in 
pregnancy with macrosomia and offspring body mass index, waist and fat mass in later 
childhood: findings from a prospective pregnancy cohort, Diabetologia 53(1) (2010) 89-97. 
[10] G.H. Son, J.Y. Kwon, Y.H. Kim, Y.W. Park, Maternal serum triglycerides as predictive 
factors for large-for-gestational age newborns in women with gestational diabetes mellitus, 
Acta Obstet Gynecol Scand 89(5) (2010) 700-4. 
[11] E. Herrera, H. Ortega-Senovilla, Disturbances in lipid metabolism in diabetic pregnancy - 
Are these the cause of the problem?, Best Pract Res Clin Endocrinol Metab 24(4) (2010) 515-
25. 
[12] U.M. Schaefer-Graf, K. Graf, I. Kulbacka, S.L. Kjos, J. Dudenhausen, K. Vetter, E. Herrera, 
Maternal lipids as strong determinants of fetal environment and growth in pregnancies with 
gestational diabetes mellitus, Diabetes Care 31(9) (2008) 1858-63. 
[13] C. Durnwald, L. Huston-Presley, S. Amini, P. Catalano, Evaluation of body composition 
of large-for-gestational-age infants of women with gestational diabetes mellitus compared 
with women with normal glucose tolerance levels, Am J Obstet Gynecol 191(3) (2004) 804-8. 
[14] C. Kim, K.M. Newton, R.H. Knopp, Gestational diabetes and the incidence of type 2 
diabetes: a systematic review, Diabetes Care 25(10) (2002) 1862-8. 
[15] D. Dabelea, D.J. Pettitt, Intrauterine diabetic environment confers risks for type 2 
diabetes mellitus and obesity in the offspring, in addition to genetic susceptibility, J Pediatr 
Endocrinol Metab 14(8) (2001) 1085-91. 
[16] E. Taricco, T. Radaelli, M.S. Nobile de Santis, I. Cetin, Foetal and placental weights in 
relation to maternal characteristics in gestational diabetes, Placenta 24(4) (2003) 343-7. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16 
[17] A. Edu, C. Teodorescu, C.G. Dobjanschi, Z.Z. Socol, V. Teodorescu, A. Matei, D.F. Albu, G. 
Radulian, Placenta changes in pregnancy with gestational diabetes, Rom J Morphol Embryol 
57(2) (2016) 507-12. 
[18] T. Jansson, M. Wennergren, T.L. Powell, Placental glucose transport and GLUT 1 
expression in insulin-dependent diabetes, Am J Obstet Gynecol 180(1 Pt 1) (1999) 163-8. 
[19] F. Visiedo, F. Bugatto, C. Carrasco-Fernandez, A. Saez-Benito, R.M. Mateos, I. Cozar-
Castellano, J.L. Bartha, G. Perdomo, Hepatocyte growth factor is elevated in amniotic fluid 
from obese women and regulates placental glucose and fatty acid metabolism, Placenta 
36(4) (2015) 381-8. 
[20] W.W. Hay, Jr., The placenta. Not just a conduit for maternal fuels, Diabetes 40 Suppl 2 
(1991) 44-50. 
[21] E. Larque, M. Ruiz-Palacios, B. Koletzko, Placental regulation of fetal nutrient supply, 
Curr Opin Clin Nutr Metab Care 16(3) (2013) 292-7. 
[22] P.M. Catalano, S. Hauguel-De Mouzon, Is it time to revisit the Pedersen hypothesis in 
the face of the obesity epidemic?, Am J Obstet Gynecol 204(6) (2011) 479-87. 
[23] S. Hauguel, J.C. Challier, L. Cedard, G. Olive, Metabolism of the human placenta 
perfused in vitro: glucose transfer and utilization, O2 consumption, lactate and ammonia 
production, Pediatr Res 17(9) (1983) 729-32. 
[24] S. Kalhan, P. Parimi, Gluconeogenesis in the fetus and neonate, Semin Perinatol 24(2) 
(2000) 94-106. 
[25] B.C. Staat, H.L. Galan, J.E. Harwood, G. Lee, A.M. Marconi, C.L. Paolini, A. Cheung, F.C. 
Battaglia, Transplacental supply of mannose and inositol in uncomplicated pregnancies 
using stable isotopes, J Clin Endocrinol Metab 97(7) (2012) 2497-502. 
[26] N.P. Illsley, Glucose transporters in the human placenta, Placenta 21(1) (2000) 14-22. 
[27] T. Jansson, M. Wennergren, N.P. Illsley, Glucose transporter protein expression in 
human placenta throughout gestation and in intrauterine growth retardation, J Clin 
Endocrinol Metab 77(6) (1993) 1554-62. 
[28] S. Hauguel-de Mouzon, J.C. Challier, A. Kacemi, M. Cauzac, A. Malek, J. Girard, The 
GLUT3 glucose transporter isoform is differentially expressed within human placental cell 
types, J Clin Endocrinol Metab 82(8) (1997) 2689-94. 
[29] L. Gao, C. Lv, C. Xu, Y. Li, X. Cui, H. Gu, X. Ni, Differential regulation of glucose 
transporters mediated by CRH receptor type 1 and type 2 in human placental trophoblasts, 
Endocrinology 153(3) (2012) 1464-71. 
[30] R. Augustin, M.O. Carayannopoulos, L.O. Dowd, J.E. Phay, J.F. Moley, K.H. Moley, 
Identification and characterization of human glucose transporter-like protein-9 (GLUT9): 
alternative splicing alters trafficking, J Biol Chem 279(16) (2004) 16229-36. 
[31] K.P. Bibee, N.P. Illsley, K.H. Moley, Asymmetric syncytial expression of GLUT9 splice 
variants in human term placenta and alterations in diabetic pregnancies, Reprod Sci 18(1) 
(2011) 20-7. 
[32] A.Y. Xing, J.C. Challier, J. Lepercq, M. Cauzac, M.J. Charron, J. Girard, S. Hauguel-de 
Mouzon, Unexpected expression of glucose transporter 4 in villous stromal cells of human 
placenta, J Clin Endocrinol Metab 83(11) (1998) 4097-101. 
[33] A.M. Holme, M.C. Roland, B. Lorentzen, T.M. Michelsen, T. Henriksen, Placental glucose 
transfer: a human in vivo study, PLoS One 10(2) (2015) e0117084. 
[34] S. Hauguel-de Mouzon, E. Shafrir, Carbohydrate and fat metabolism and related 
hormonal regulation in normal and diabetic placenta, Placenta 22(7) (2001) 619-27. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
[35] H. Schneider, Placental oxygen consumption. Part II: in vitro studies--a review, Placenta 
21 Suppl A (2000) S38-44. 
[36] C.J. Jones, G. Desoye, Glycogen distribution in the capillaries of the placental villus in 
normal, overt and gestational diabetic pregnancy, Placenta 14(5) (1993) 505-17. 
[37] F. Visiedo, F. Bugatto, V. Sanchez, I. Cozar-Castellano, J.L. Bartha, G. Perdomo, High 
glucose levels reduce fatty acid oxidation and increase triglyceride accumulation in human 
placenta, Am J Physiol Endocrinol Metab 305(2) (2013) E205-12. 
[38] S. Matsubara, T. Takizawa, I. Sato, Glucose-6-phosphatase is present in normal and pre-
eclamptic placental trophoblasts: ultrastructural enzyme-histochemical evidence, Placenta 
20(1) (1999) 81-5. 
[39] O. Acosta, V.I. Ramirez, S. Lager, F. Gaccioli, D.J. Dudley, T.L. Powell, T. Jansson, 
Increased glucose and placental GLUT-1 in large infants of obese nondiabetic mothers, Am J 
Obstet Gynecol 212(2) (2015) 227 e1-7. 
[40] K.A. Roberts, S.C. Riley, R.M. Reynolds, S. Barr, M. Evans, A. Statham, K. Hor, H.N. 
Jabbour, J.E. Norman, F.C. Denison, Placental structure and inflammation in pregnancies 
associated with obesity, Placenta 32(3) (2011) 247-54. 
[41] N. Di Simone, F. Di Nicuolo, D. Marzioni, M. Castellucci, M. Sanguinetti, S. D'Lppolito, A. 
Caruso, Resistin modulates glucose uptake and glucose transporter-1 (GLUT-1) expression in 
trophoblast cells, J Cell Mol Med 13(2) (2009) 388-97. 
[42] S. Muralimanoharan, C. Guo, L. Myatt, A. Maloyan, Sexual dimorphism in miR-210 
expression and mitochondrial dysfunction in the placenta with maternal obesity, Int J Obes 
(Lond) 39(8) (2015) 1274-81. 
[43] P. Dandona, H.S. Besterman, D.B. Freedman, F. Boag, A.M. Taylor, A.G. Beckett, 
Macrosomia despite well-controlled diabetic pregnancy, Lancet 1(8379) (1984) 737. 
[44] B. Persson, U. Hanson, Fetal size at birth in relation to quality of blood glucose control 
in pregnancies complicated by pregestational diabetes mellitus, Br J Obstet Gynaecol 103(5) 
(1996) 427-33. 
[45] K. Gaither, A.N. Quraishi, N.P. Illsley, Diabetes alters the expression and activity of the 
human placental GLUT1 glucose transporter, J Clin Endocrinol Metab 84(2) (1999) 695-701. 
[46] N.P. Illsley, M.C. Sellers, R.L. Wright, Glycaemic regulation of glucose transporter 
expression and activity in the human placenta, Placenta 19(7) (1998) 517-24. 
[47] F. Visiedo, F. Bugatto, R. Quintero-Prado, I. Cozar-Castellano, J.L. Bartha, G. Perdomo, 
Glucose and Fatty Acid Metabolism in Placental Explants From Pregnancies Complicated 
With Gestational Diabetes Mellitus, Reprod Sci 22(7) (2015) 798-801. 
[48] R. Hastie, M. Lappas, The effect of pre-existing maternal obesity and diabetes on 
placental mitochondrial content and electron transport chain activity, Placenta 35(9) (2014) 
673-83. 
[49] S. Muralimanoharan, A. Maloyan, L. Myatt, Mitochondrial function and glucose 
metabolism in the placenta with gestational diabetes mellitus: role of miR-143, Clin Sci 
(Lond) 130(11) (2016) 931-41. 
[50] M.E. Baardman, J.J. Erwich, R.M. Berger, R.M. Hofstra, W.S. Kerstjens-Frederikse, D. 
Lutjohann, T. Plosch, The origin of fetal sterols in second-trimester amniotic fluid: 
endogenous synthesis or maternal-fetal transport?, Am J Obstet Gynecol 207(3) (2012) 202 
e19-25. 
[51] G. Desoye, M. Gauster, C. Wadsack, Placental transport in pregnancy pathologies, Am J 
Clin Nutr  (2011). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
18 
[52] A. Gil-Sanchez, B. Koletzko, E. Larque, Current understanding of placental fatty acid 
transport, Curr Opin Clin Nutr Metab Care 15(3) (2012) 265-72. 
[53] M.L. Lindegaard, P. Damm, E.R. Mathiesen, L.B. Nielsen, Placental triglyceride 
accumulation in maternal type 1 diabetes is associated with increased lipase gene 
expression, J Lipid Res 47(11) (2006) 2581-8. 
[54] A.L. Magnusson, I.J. Waterman, M. Wennergren, T. Jansson, T.L. Powell, Triglyceride 
hydrolase activities and expression of fatty acid binding proteins in the human placenta in 
pregnancies complicated by intrauterine growth restriction and diabetes, J Clin Endocrinol 
Metab 89(9) (2004) 4607-14. 
[55] T. Radaelli, J. Lepercq, A. Varastehpour, S. Basu, P.M. Catalano, S. Hauguel-De Mouzon, 
Differential regulation of genes for fetoplacental lipid pathways in pregnancy with 
gestational and type 1 diabetes mellitus, American journal of obstetrics and gynecology 
201(2) (2009) 209 e1-209 e10. 
[56] E. Dubé, A. Gravel, C. Martin, G. Desparois, I. Moussa, M. Ethier-Chiasson, J.-C. Forest, 
Y. Giguère, A. Masse, J. Lafond, Modulation of Fatty Acid Transport and Metabolism by 
Maternal Obesity in the Human Full-Term Placenta, Biology of Reproduction 87(1) (2012) 
14, 1-11. 
[57] M. Gauster, U. Hiden, M. van Poppel, S. Frank, C. Wadsack, S. Hauguel-de Mouzon, G. 
Desoye, Dysregulation of placental endothelial lipase in obese women with gestational 
diabetes mellitus, Diabetes 60(10) (2011) 2457-64. 
[58] H.L. Barrett, M.H. Kubala, K. Scholz Romero, K.J. Denny, T.M. Woodruff, H.D. McIntyre, 
L.K. Callaway, M.D. Nitert, Placental lipases in pregnancies complicated by gestational 
diabetes mellitus (GDM), PLoS One 9(8) (2014) e104826. 
[59] M. Gauster, U. Hiden, A. Blaschitz, S. Frank, U. Lang, G. Alvino, I. Cetin, G. Desoye, C. 
Wadsack, Dysregulation of placental endothelial lipase and lipoprotein lipase in intrauterine 
growth-restricted pregnancies, J Clin Endocrinol Metab 92(6) (2007) 2256-63. 
[60] L.A. Woollett, Review: Transport of maternal cholesterol to the fetal circulation, 
Placenta 32 Suppl 2 (2011) S218-21. 
[61] S.L. Rebholz, K.T. Burke, Q. Yang, P. Tso, L.A. Woollett, Dietary fat impacts fetal growth 
and metabolism: uptake of chylomicron remnant core lipids by the placenta, Am J Physiol 
Endocrinol Metab 301(2) (2011) E416-25. 
[62] S.H. Mouzon, L. Lassance, Endocrine and metabolic adaptations to pregnancy; impact of 
obesity, Hormone molecular biology and clinical investigation 24(1) (2015) 65-72. 
[63] E. Dos Santos, F. Duval, F. Vialard, M.N. Dieudonne, The roles of leptin and adiponectin 
at the fetal-maternal interface in humans, Hormone molecular biology and clinical 
investigation 24(1) (2015) 47-63. 
[64] F.J. Rosario, T.L. Powell, T. Jansson, Activation of placental insulin and mTOR signaling in 
a mouse model of maternal obesity associated with fetal overgrowth, Am J Physiol Regul 
Integr Comp Physiol 310(1) (2016) R87-93. 
[65] I.L. Aye, F.J. Rosario, T.L. Powell, T. Jansson, Adiponectin supplementation in pregnant 
mice prevents the adverse effects of maternal obesity on placental function and fetal 
growth, Proc Natl Acad Sci U S A 112(41) (2015) 12858-63. 
[66] M.J. Zhu, Y. Ma, N.M. Long, M. Du, S.P. Ford, Maternal obesity markedly increases 
placental fatty acid transporter expression and fetal blood triglycerides at midgestation in 
the ewe, Am J Physiol Regul Integr Comp Physiol 299(5) (2010) R1224-31. 
[67] P. Diaz, J. Harris, F.J. Rosario, T.L. Powell, T. Jansson, Increased placental fatty acid 
transporter 6 and binding protein 3 expression and fetal liver lipid accumulation in a mouse 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
model of obesity in pregnancy, Am J Physiol Regul Integr Comp Physiol 309(12) (2015) 
R1569-77. 
[68] L. Lassance, M. Haghiac, P. Leahy, S. Basu, J. Minium, J. Zhou, M. Reider, P.M. Catalano, 
S. Hauguel-de Mouzon, Identification of early transcriptome signatures in placenta exposed 
to insulin and obesity, Am J Obstet Gynecol 212(5) (2015) 647.e1-11. 
[69] C. Marseille-Tremblay, M. Ethier-Chiasson, J.C. Forest, Y. Giguere, A. Masse, C. Mounier, 
J. Lafond, Impact of maternal circulating cholesterol and gestational diabetes mellitus on 
lipid metabolism in human term placenta, Mol Reprod Dev 75(6) (2008) 1054-62. 
[70] L. Lassance, M. Haghiac, J. Minium, P. Catalano, S. Hauguel-de Mouzon, Obesity-
induced down-regulation of the mitochondrial translocator protein (TSPO) impairs placental 
steroid production, J Clin Endocrinol Metab 100(1) (2015) E11-8. 
[71] K.E. Brett, Z.M. Ferraro, M. Holcik, K.B. Adamo, Placenta nutrient transport-related 
gene expression: the impact of maternal obesity and excessive gestational weight gain, J 
Matern Fetal Neonatal Med 29(9) (2016) 1399-405. 
[72] E. Brass, E. Hanson, P.F. O'Tierney-Ginn, Placental oleic acid uptake is lower in male 
offspring of obese women, Placenta 34(6) (2013) 503-9. 
[73] P. O'Tierney-Ginn, L. Presley, S. Myers, P. Catalano, Placental growth response to 
maternal insulin in early pregnancy, J Clin Endocrinol Metab 100(1) (2015) 159-65. 
[74] A. Perez-Perez, P. Guadix, J. Maymo, J.L. Duenas, C. Varone, M. Fernandez-Sanchez, V. 
Sanchez-Margalet, Insulin and Leptin Signaling in Placenta from Gestational Diabetic 
Subjects, Horm Metab Res 48(1) (2016) 62-9. 
[75] S. Baumuller, H. Lehnen, J. Schmitz, R. Fimmers, A.M. Muller, The impact of insulin 
treatment on the expression of vascular endothelial cadherin and Beta-catenin in human 
fetoplacental vessels, Pediatr Dev Pathol 18(1) (2015) 17-23. 
[76] E. Capobianco, N. Martinez, D. Fornes, R. Higa, I. Di Marco, M.N. Basualdo, M.C. 
Faingold, A. Jawerbaum, PPAR activation as a regulator of lipid metabolism, nitric oxide 
production and lipid peroxidation in the placenta from type 2 diabetic patients, Mol Cell 
Endocrinol 377(1-2) (2013) 7-15. 
[77] E. Dubé, M. Ethier-Chiasson, J. Lafond, Modulation of Cholesterol Transport by Insulin-
Treated Gestational Diabetes Mellitus in Human Full-Term Placenta, Biology of 
Reproduction 88(1) (2013) 16, 1-10. 
[78] S. Lager, A. Magnusson-Olsson, T. Powell, T. Jansson, Placental lipoprotein lipase 
activity is decreased by elevated free fatty acids, Placenta 27(9-10) (2006) A35-A35. 
[79] A.L. Magnusson-Olsson, S. Lager, B. Jacobsson, T. Jansson, T.L. Powell, Effect of 
maternal triglycerides and free fatty acids on placental LPL in cultured primary trophoblast 
cells and in a case of maternal LPL deficiency, Am J Physiol Endocrinol Metab 293(1) (2007) 
E24-30. 
[80] A.A. Houde, J. St-Pierre, M.F. Hivert, J.P. Baillargeon, P. Perron, D. Gaudet, D. Brisson, L. 
Bouchard, Placental lipoprotein lipase DNA methylation levels are associated with 
gestational diabetes mellitus and maternal and cord blood lipid profiles, J Dev Orig Health 
Dis 5(2) (2014) 132-41. 
[81] M. Scholler, C. Wadsack, I. Lang, K. Etschmaier, C. Schweinzer, G. Marsche, M. Dieber-
Rotheneder, G. Desoye, U. Panzenboeck, Phospholipid transfer protein in the placental 
endothelium is affected by gestational diabetes mellitus, J Clin Endocrinol Metab 97(2) 
(2012) 437-45. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
[82] A.J. Szabo, O. Szabo, Placental free-fatty-acid transfer and fetal adipose-tissue 
development: an explantation of fetal adiposity in infants of diabetic mothers, Lancet 
2(7879) (1974) 498-9. 
[83] J.R. Araujo, A. Correia-Branco, C. Ramalho, E. Keating, F. Martel, Gestational diabetes 
mellitus decreases placental uptake of long-chain polyunsaturated fatty acids: involvement 
of long-chain acyl-CoA synthetase, J Nutr Biochem 24(10) (2013) 1741-50. 
[84] T.M. Coltart, C. Bateman, Carbohydrate-induced lipogenesis in the human placenta of 
normal and diabetic pregnancies, Br J Obstet Gynaecol 82(6) (1975) 471-5. 
[85] J.S. Camelo Jr, S.M. Jorge, F.E. Martinez, Amino acid composition of parturient plasma, 
the intervillous space of the placenta and the umbilical vein of term newborn infants, 
Brazilian Journal of Medical and Biological Research 37 (2004) 711-717. 
[86] D.L. Yudilevich, J.H. Sweiry, Transport of amino acids in the placenta, Biochimica et 
Biophysica Acta (BBA) - Reviews on Biomembranes 822(2) (1985) 169-201. 
[87] T. Jansson, Y. Ekstrand, C. Bjorn, M. Wennergren, T.L. Powell, Alterations in the activity 
of placental amino acid transporters in pregnancies complicated by diabetes, Diabetes 51(7) 
(2002) 2214-9. 
[88] T. Jansson, Amino acid transporters in the human placenta, Pediatr Res 49(2) (2001) 
141-7. 
[89] X. Wu, C. Xie, Y. Zhang, Z. Fan, Y. Yin, F. Blachier, Glutamate–glutamine cycle and 
exchange in the placenta–fetus unit during late pregnancy, Amino acids 47(1) (2015) 45-53. 
[90] N. Jansson, F.J. Rosario, F. Gaccioli, S. Lager, H.N. Jones, S. Roos, T. Jansson, T.L. Powell, 
Activation of Placental mTOR Signaling and Amino Acid Transporters in Obese Women 
Giving Birth to Large Babies, The Journal of Clinical Endocrinology & Metabolism 98(1) 
(2012) 105-113. 
[91] D.M. Farley, J. Choi, D.J. Dudley, C. Li, S.L. Jenkins, L. Myatt, P.W. Nathanielsz, Placental 
amino acid transport and placental leptin resistance in pregnancies complicated by maternal 
obesity, Placenta 31(8) (2010) 718-24. 
[92] H.N. Jones, T. Jansson, T.L. Powell, IL-6 stimulates system A amino acid transporter 
activity in trophoblast cells through STAT3 and increased expression of SNAT2, American 
Journal of Physiology - Cell Physiology 297(5) (2009) C1228. 
[93] K.E. Brett, Z.M. Ferraro, M. Holcik, K.B. Adamo, Placenta nutrient transport-related 
gene expression: the impact of maternal obesity and excessive gestational weight gain, The 
Journal of Maternal-Fetal & Neonatal Medicine 29(9) (2016) 1399-1405. 
[94] H.N. Jones, L.A. Woollett, N. Barbour, P.D. Prasad, T.L. Powell, T. Jansson, High-fat diet 
before and during pregnancy causes marked up-regulation of placental nutrient transport 
and fetal overgrowth in 57/BL6 mice, FASEB journal : official publication of the Federation 
of American Societies for Experimental Biology 23(1) (2009) 271-8. 
[95] F. Gaccioli, I.L.M.H. Aye, S. Roos, S. Lager, V.I. Ramirez, Y. Kanai, T.L. Powell, T. Jansson, 
Expression and functional characterisation of System L amino acid transporters in the 
human term placenta, Reproductive Biology and Endocrinology 13(1) (2015) 1-10. 
[96] M. Desforges, C. Hirst, M. Price, S. Greenwood, Taurine in normal pregnancy and 
preeclampsia: Fetal-placental-maternal cross talk, Placenta 35(9) (2014) A87. 
[97] A.M. Ditchfield, M. Desforges, T.A. Mills, J.D. Glazier, M. Wareing, K. Mynett, C.P. Sibley, 
S.L. Greenwood, Maternal obesity is associated with a reduction in placental taurine 
transporter activity, Int J Obes 39(4) (2015) 557-564. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21 
[98] N. Jansson, S.L. Greenwood, B.R. Johansson, T.L. Powell, T. Jansson, Leptin Stimulates 
the Activity of the System A Amino Acid Transporter in Human Placental Villous Fragments, 
The Journal of Clinical Endocrinology & Metabolism 88(3) (2003) 1205-1211. 
[99] S. Roos, O. Lagerlöf, M. Wennergren, T.L. Powell, T. Jansson, Regulation of amino acid 
transporters by glucose and growth factors in cultured primary human trophoblast cells is 
mediated by mTOR signaling, American Journal of Physiology - Cell Physiology 297(3) (2009) 
C723. 
[100] R.K. Kalkhoff, E. Kandaraki, P.G. Morrow, T.H. Mitchell, S. Kelber, H.I. Borkowf, 
Relationship between neonatal birth weight and maternal plasma amino acid profiles in lean 
and obese nondiabetic women and in type I diabetic pregnant women, Metabolism 37(3) 
(1988) 234-9. 
[101] A.G. Kuruvilla, S.W. D'Souza, J.D. Glazier, D. Mahendran, M.J. Maresh, C.P. Sibley, 
Altered activity of the system A amino acid transporter in microvillous membrane vesicles 
from placentas of macrosomic babies born to diabetic women, J Clin Invest 94(2) (1994) 
689-95. 
[102] I. Cetin, M.S. de Santis, E. Taricco, T. Radaelli, C. Teng, S. Ronzoni, E. Spada, S. Milani, 
G. Pardi, Maternal and fetal amino acid concentrations in normal pregnancies and in 
pregnancies with gestational diabetes mellitus, Am J Obstet Gynecol 192(2) (2005) 610-7. 
[103] T. Jansson, Y. Ekstrand, C. Björn, M. Wennergren, T.L. Powell, Alterations in the 
Activity of Placental Amino Acid Transporters in Pregnancies Complicated by Diabetes, 
Diabetes 51(7) (2002) 2214. 
[104] J.R. Araujo, A. Correia-Branco, C. Ramalho, P. Goncalves, M.J. Pinho, E. Keating, F. 
Martel, L-methionine placental uptake: characterization and modulation in gestational 
diabetes mellitus, Reprod Sci 20(12) (2013) 1492-507. 
[105] C. Marseille-Tremblay, M. Ethier-Chiasson, J.-C. Forest, Y. Giguère, A. Masse, C. 
Mounier, J. Lafond, Impact of maternal circulating cholesterol and gestational diabetes 
mellitus on lipid metabolism in human term placenta, Molecular Reproduction and 
Development 75(6) (2008) 1054-1062. 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table X Amino acid transporters in the placenta 
 
Name Amino acids preference for transport 
Neutral amino acid transporters 
System A alanine, serine, glutamine 
System B taurine, β-alanine 
System L leucine, phenylalanine 
System N glutamine, asparagine, histidine 
System T tyrosine 
System ASC cysteine, alanine, serine 
System Gly glycine, sarcosine 
Cationic amino acid transporters 
System y
+
 arginine, lysine 
System b
0,+
 arginine, lysine 
System y
+
L arginine, lysine 
Anionic amino acid transporters 
System X
-
AG aspartate, glutamate 
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Figure legends 
 
 
Figure 1 Placental transfer and metabolism of energy substrates in maternal overweight, 
obesity, and/or diabetes mellitus. Maternal circulating levels of glucose, fatty 
acids/cholesterol, and amino acids may be altered. Glucose: The expression of GLUTs 
remains unaffected in the microvillous membrane but is upregulated in the basal 
membrane, facilitating enhanced glucose transport across the placental-fetal side. Placental 
metabolism of glucose (glycolysis) is also enhanced. Fatty acids/cholesterol: The expression 
of some lipases and FABPs are increased allowing for enhanced maternal-fetal transfer of 
NEFAs and/or cholesterol across microvillous and basal membranes. Byproducts of 
glycolysis are thought to inhibit fatty acid oxidation (β-oxidation) shifting placental fatty acid 
metabolism to NEFA esterification and triglyceride accumulation. Amino acids: Maternal 
amino acid levels are increased in type 1 diabetes and transport via SNAT is increased. In 
obesity and GDM, amino acid levels are not altered but SNAT expression and activity are 
higher. Collectively, these modifications to substrate transport and metabolism across the 
placenta contribute to adverse fetal outcomes, the most common being macrosomia 
(weighting of block arrows signifies the magnitude of contribution). FABPs, fatty acid 
binding proteins; GLUTs, facilitated glucose transporters; IGF-1, insulin-like growth factor-1; 
LATs, system L amino acid transporters; SNATs, system A amino acid transporters; trig, 
triglycerides.  
 
Figure 2. Putative transport of lipids across the placenta. 
Fatty acids, either free or derived from lipoproteins by lipases including lipoprotein lipase 
(LPL) and endothelial lipase (EL) are transported into the placenta by multiple fatty acid 
transporters: plasma membrane fatty acid binding protein (FABPpm), fatty acid binding 
protein 1-5 (FABP1-5), fatty acid translocase (FAT)/CD36 and fatty acid transport protein 1-4 
and 6 (FATP1-4,6). The fatty acids are then either metabolized in the placenta for energy use 
or storage in lipid droplets or transported to the fetal circulation by passive diffusion or 
carried by FAT/CD36 or FATP1-4,6. The cholesterol moiety of lipoproteins can be taken up 
by the cholesterol receptors for LDL cholesterol (LDLR), for VLDR cholesterol (VLDLR) or for 
HDL cholesterol (scavenging receptor class B type 1, SR-B1). Cholesterol is then metabolized 
in the placenta or effluxed to the fetal circulation as a lipoprotein by the ATP binding 
cassette transporters A1 (ABCA1) and ABCG1).  
 
Figure 3. Circulating metabolic factors and placental amino acid transporters in obesity, 
type 1 diabetes, and gestational diabetes mellitus. In maternal obesity, metabolic 
hormones are generally elevated and there is increased expression of system A, unchanged 
expression of system L, and decreased expression of system B amino acid transporters in 
placental tissue. In maternal type 1 diabetes, metabolic hormones, with the exception of 
leptin, are elevated as are circulating concentrations of some amino acids. There are reports 
of increased and decreased system A amino acid transport in the placenta and effects on 
other amino acid transport pathways are unknown in type 1 diabetes. In gestational 
diabetes mellitus, metabolic hormones are typically elevated in the maternal circulation and 
placental system A and L transport are increased. There are no reports on placental amino 
acid transport in the setting of type 2 diabetes. IGF-1, insulin-like growth factor-1. 
 
